Brind.

Leerink Partners downgrades Akebia Therapeutics shares

1 report, 1 independent Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Leerink Partners downgraded Akebia Therapeutics shares on November 3, 2026. The biopharmaceutical company recently reported Q3 2026 results, showing revenue of $49.13 million and earnings per share of ($0.02) for the quarter, which beat analyst consensus estimates. The company is expected to release its Q3 2026 results on November 5th.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The rating change by Leerink Partners could influence investor sentiment and market perception of Akebia Therapeutics. Analysts expect the company to post ($0.14) earnings per share for the current fiscal year and ($0.27) for the next fiscal year.

From dailypolitical.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • companySpeculative

    Akebia Therapeutics might see changes in investment funding or stock demand following the rating change.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped